logo
Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?

Register
    

 


Steve Brozak sees a bubble getting larger, and he is anticipating the time when biotech stocks pull back to take a breather, like all high-flying markets ultimately do. While investors may own innovative companies with highly disruptive technologies, Brozak insists on careful diligence to find names with the potential for…
Read more...
Investing in micro- and small-cap biotech companies carries great risk, but for investors who take the time to dig out the value proposition, the upside can be phenomenal. Enter Ross Silver of Vista Partners, who publishes research and owns many of the stocks he writes about. In this interview with…
Read more...
It's been four months since The Life Sciences Report's 2015 Small-Cap Biotech Watchlist was announced at the Biotech Showcase in San Francisco. The year is off to a bumpy start, though the rough ride is not predicated, necessarily, on individual company performance. Read on for highlights of the Watchlist's Q1/15…
Read more...
An immunotherapy revolution is rocking biotechnology, and investors are searching for just the right way to play the new trend. Do you go with an unknown company where the upside could be unparalleled? Do you go with an older name that has established partnerships with major pharmas? John McCamant, editor…
Read more...
Last month saw the announcement of one the biggest UK M&A (mergers and acquisitions) deals in a while, with Royal Dutch Shell ($RDS.A) set to gobble up BG Group plc (BG)  for £47bn. That the news came from the oil and gas sector was little surprise, with low oil prices leading to some huge share price moves among major…
Read more...
Portfolio manager Bruce Campbell wants the best of both worlds in his Canadian healthcare investments. He looks for companies that are strong and balanced, with muscular organic growth on one side and healthy acquisitions on the other. In this interview with The Life Sciences Report, the founder and president of…
Read more...
Klox Technologies (KLOX) is a specialty pharmaceutical company focused on developing and commercializing products based on its proprietary BioPhotonic technology platform to address skin and soft tissue disorders. It is based in Quebec, Canada. Eleven other companies are scheduled to IPO for the week of May 4. The full IPO…
Read more...
aTYR PHARMA (LIFE) engages in the discovery and clinical development of innovative medicines for patients suffering from severe, rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological modulators. It is based in San Diego, CA. Eleven other companies are scheduled to IPO for the week…
Read more...
Gelesis (GLSS) is a biotechnology company focused on the development of first-in-class products to induce weight loss and improve glycemic control in overweight and obese patients, including those with prediabetes and type 2 diabetes. It is based in Boston, MA. Eleven other companies are scheduled for the week of May…
Read more...
MultiVir (MVIR) is a clinical-stage gene therapy company developing a pipeline of novel product candidates for the treatment of multiple oncological indications. It is based in Houston, TX. Eleven other companies are scheduled to IPO for the week of May 4. The full IPO calendar is available at IPO Premium.…
Read more...
HTG Molecular Diagnostics (HTGM) is a commercial stage company that developed and markets a novel technology platform to facilitate the routine use of complex molecular profiling. It is based in Tucson, AZ. Eleven other companies are scheduled to IPO for the week of May 4. The full IPO calendar is…
Read more...
May is National Stroke Awareness Month. Let me tell you a secret. I am a stroke survivor. It’s been more than 10 years since my life changed in the blink of an eye. My recovery took years. However, I consider myself fortunate because I fought my way back. Now I…
Read more...
Page 1 of 52

About us

Equities.com is the most advanced interactive online social ecosystem for the financial industry, serving as a resource center and next-generation communication platform that connects self-directed investors with public issuers, market experts, and professional service providers and vendors. Registered members can leverage our exclusive proprietary research tools such as the Small-Cap Stars, which outperformed 90% of all small-cap mutual funds, and robust do-it-yourself E.V.A. research reports. The Equities.com Issuer Dashboard is the ideal tool to communicate and manage investor awareness campaigns to the investment community, as well as to access valuable resources to help your company grow.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.

Login or Register

LOG IN